National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$35.50
add to cart

Rights & Permissions

topleft topright

The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa: Global and Local Challenges and Solutions: Workshop Summary (2011)
Board on Health Sciences Policy (HSP)

Citation Manager

. "1 Introduction." The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa: Global and Local Challenges and Solutions: Workshop Summary. Washington, DC: The National Academies Press, 2011.

Please select a format:

BibTeX EndNote RefMan


Page
2
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa: Global and Local Challenges and Solutions - Summary of a Joint Workshop by the Institute of Medicine and the Academy of Science of South Africa

BOX 1-1a

The Nature of the Threat


Definitions


Multidrug-resistant tuberculosis (MDR TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally introduced in the 1950s.

Extensively drug-resistant tuberculosis (XDR TB) is resistant to the same drugs as MDR TB (isoniazid and rifampicin), as well as any fluoroquinolone (levofloxacin, moxifloxacin, or ofloxacin) and at least one second-line injectable drug (kanamycin, amikacin, or capreomycin).

Totally drug-resistant tuberculosis (TDR TB) is TB for which no effective treatments are available.


Pathways for Infection


MDR/XDR TB results from either primary infection with a drug-resistant strain of TB (i.e., transmitted by person-to-person contact) or acquired infection with such a strain that occurs in the course of a patient’s treatment, resulting, for example, from failure to ensure regular treatment with high-quality drugs. Amplified resistance, or the enhancement of existing drug resistance as a result of initiating an inappropriate drug regimen at the beginning of care, is a significant challenge created by providing an incorrect combination of drugs. Even when an empirically appropriate drug regimen is selected at the beginning of treatment, by the time drug susceptibility information is available, resistance may be amplified.


Treatment


Treatment of MDR and XDR TB requires 2 years or more of daily, directly observed treatment with drugs that are less potent, more toxic, and much more expensive than those used to treat drug-susceptible TB. Despite the challenges, aggressive treatment with second-line drugs has produced successful outcomes in MDR and XDR TB patients. However, TDR TB is a growing threat. The spread of TDR TB is especially ominous as it would return the globe to the pre-antibiotic era with respect to this disease. Identifying and addressing barriers to effective and timely diagnosis and treatment of drug-resistant TB supports prevention of the further emergence of strains of TB with broad-spectrum resistance (Keshavjee and Seung, 2008).

  

aThe information in this box was originally presented at the Forum’s 2008 workshop on drug-resistant TB (IOM, 2009).

Page
2